Follow the people · Insider
Jeffrey Bluestone
Jeffrey Bluestone files insider transactions with the SEC as a director of Gilead Sciences (GILD). We hold 2 disclosed purchases and sales filed since 28 March 2019, 1 of them in the last 90 days.
- Files forGILD
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure21 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 8 December 2020 — 20 August 2026Director · Gilead Sciences (GILD)47 Form 4 lines · source: SEC Form 4
- Filed 27 March 2019 — 17 May 2022Director · Provention Bio (PRVB)12 Form 4 lines · source: SEC Form 4
Everything they disclosed
59 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 1,165 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 335 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 4,665 shares of Gilead Sciences (a derivative holding)SEC Form 421 August 2026Non-qualified Stock Option (Right to Buy) · traded 20 August 2026 · filed 21 August 2026
- exercised options over 335 shares of Gilead Sciences (a derivative holding)SEC Form 421 August 2026Non-qualified Stock Option (Right to Buy) · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 1,165 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 1,816 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 1,816 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 1,658 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 1,658 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 26 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 26 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 335 shares of Gilead SciencesSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- was granted 1,146 shares of Gilead SciencesSEC Form 44 May 2026Common Stock · traded 30 April 2026 · filed 4 May 2026
- was granted 4,884 shares of Gilead Sciences (a derivative holding)SEC Form 44 May 2026Non-qualified Stock Option (Right to Buy) · traded 30 April 2026 · filed 4 May 2026
- exercised options over 5,000 shares of Gilead SciencesSEC Form 421 January 2026Common Stock · traded 20 January 2026 · filed 21 January 2026
- ▼ sold on the open market 5,000 shares of Gilead SciencesSEC Form 421 January 2026Common Stock · traded 20 January 2026 · filed 21 January 2026
- exercised options over 5,000 shares of Gilead Sciences (a derivative holding)SEC Form 421 January 2026Non-qualified Stock Option (Right to Buy) · traded 20 January 2026 · filed 21 January 2026
- exercised options over 5,000 shares of Gilead Sciences (a derivative holding)SEC Form 421 January 2026Non-qualified Stock Option (Right to Buy) · traded 20 January 2026 · filed 21 January 2026
- exercised options over 5,000 shares of Gilead SciencesSEC Form 421 January 2026Common Stock · traded 20 January 2026 · filed 21 January 2026
- ▼ sold on the open market 5,000 shares of Gilead SciencesSEC Form 421 January 2026Common Stock · traded 20 January 2026 · filed 21 January 2026
- exercised options over 5,000 shares of Gilead Sciences (a derivative holding)SEC Form 41 December 2025Non-qualified Stock Option (Right to Buy) · traded 28 November 2025 · filed 1 December 2025
- exercised options over 5,000 shares of Gilead SciencesSEC Form 41 December 2025Common Stock · traded 28 November 2025 · filed 1 December 2025
- ▼ sold on the open market 5,000 shares of Gilead SciencesSEC Form 41 December 2025Common Stock · traded 28 November 2025 · filed 1 December 2025
- exercised options over 5,000 shares of Gilead Sciences (a derivative holding)SEC Form 415 July 2025Non-qualified Stock Option (Right to Buy) · traded 14 July 2025 · filed 15 July 2025
- exercised options over 5,000 shares of Gilead SciencesSEC Form 415 July 2025Common Stock · traded 14 July 2025 · filed 15 July 2025
- ▼ sold on the open market 5,000 shares of Gilead SciencesSEC Form 415 July 2025Common Stock · traded 14 July 2025 · filed 15 July 2025
- was granted 1,516 shares of Gilead Sciences (a derivative holding)SEC Form 48 May 2025Restricted Stock Unit · traded 7 May 2025 · filed 8 May 2025
- was granted 6,809 shares of Gilead Sciences (a derivative holding)SEC Form 48 May 2025Non-qualified Stock Option (Right to Buy) · traded 7 May 2025 · filed 8 May 2025
- exercised options over 5,879 shares of Gilead Sciences (a derivative holding)SEC Form 427 November 2024Non-qualified Stock Option (Right to Buy) · traded 26 November 2024 · filed 27 November 2024
- exercised options over 4,121 shares of Gilead Sciences (a derivative holding)SEC Form 427 November 2024Non-qualified Stock Option (Right to Buy) · traded 26 November 2024 · filed 27 November 2024
- exercised options over 5,879 shares of Gilead SciencesSEC Form 427 November 2024Common Stock · traded 26 November 2024 · filed 27 November 2024
- exercised options over 4,121 shares of Gilead SciencesSEC Form 427 November 2024Common Stock · traded 26 November 2024 · filed 27 November 2024
- ▼ sold on the open market 6,788 shares of Gilead SciencesSEC Form 427 November 2024Common Stock · traded 26 November 2024 · filed 27 November 2024
- was granted 2,310 shares of Gilead Sciences (a derivative holding)SEC Form 49 May 2024Restricted Stock Unit · traded 8 May 2024 · filed 9 May 2024
- was granted 12,648 shares of Gilead Sciences (a derivative holding)SEC Form 49 May 2024Non-qualified Stock Option (Right to Buy) · traded 8 May 2024 · filed 9 May 2024
- was granted 1,887 shares of Gilead Sciences (a derivative holding)SEC Form 44 May 2023Restricted Stock Unit · traded 3 May 2023 · filed 4 May 2023
- was granted 10,173 shares of Gilead Sciences (a derivative holding)SEC Form 44 May 2023Non-qualified Stock Option (Right to Buy) · traded 3 May 2023 · filed 4 May 2023
- was granted 33,000 shares of Provention Bio (a derivative holding)SEC Form 418 May 2022Stock Option (right to buy) · traded 17 May 2022 · filed 18 May 2022
- was granted 15,851 shares of Gilead Sciences (a derivative holding)SEC Form 46 May 2022Non-qualified Stock Option (Right to Buy) · traded 5 May 2022 · filed 6 May 2022
- was granted 2,444 shares of Gilead SciencesSEC Form 46 May 2022Common Stock · traded 5 May 2022 · filed 6 May 2022
- exercised options over 2,223 shares of Gilead Sciences (a derivative holding)SEC Form 43 May 2022Restricted Stock Unit · traded 3 May 2022 · filed 3 May 2022
- exercised options over 2,223 shares of Gilead SciencesSEC Form 43 May 2022Common Stock · traded 3 May 2022 · filed 3 May 2022
- exercised options over 1,041 shares of Gilead Sciences (a derivative holding)SEC Form 49 December 2021Restricted Stock Unit · traded 8 December 2021 · filed 9 December 2021
- exercised options over 1,041 shares of Gilead SciencesSEC Form 49 December 2021Common Stock · traded 8 December 2021 · filed 9 December 2021
- was granted 2,223 shares of Gilead Sciences (a derivative holding)SEC Form 414 May 2021Restricted Stock Unit · traded 12 May 2021 · filed 14 May 2021
- was granted 14,665 shares of Gilead Sciences (a derivative holding)SEC Form 414 May 2021Non-qualified Stock Option (Right to Buy) · traded 12 May 2021 · filed 14 May 2021
- was granted 23,000 shares of Provention Bio (a derivative holding)SEC Form 414 May 2021Stock Option (right to buy) · traded 12 May 2021 · filed 14 May 2021
- was granted 5,879 shares of Gilead Sciences (a derivative holding)SEC Form 410 December 2020Non-qualified Stock Option (Right to Buy) · traded 8 December 2020 · filed 10 December 2020
- was granted 1,041 shares of Gilead Sciences (a derivative holding)SEC Form 410 December 2020Restricted Stock Unit · traded 8 December 2020 · filed 10 December 2020
- was granted 22,200 shares of Provention Bio (a derivative holding)SEC Form 416 July 2020Option (right to buy) · traded 15 July 2020 · filed 16 July 2020
- gave away 128,981 shares of Provention Bio (a derivative holding)SEC Form 414 April 2020Employee Stock Option (right to buy) · traded 27 February 2020 · filed 14 April 2020
- gave away 128,981 shares of Provention Bio (a derivative holding)SEC Form 414 April 2020Employee Stock Option (right to buy) · traded 27 February 2020 · filed 14 April 2020
- exercised options over 32,246 shares of Provention Bio (a derivative holding)SEC Form 414 April 2020Employee Stock Option (right to buy) · traded 10 April 2020 · filed 14 April 2020
- gave away 24,000 shares of Provention Bio (a derivative holding)SEC Form 414 April 2020Employee Stock Option (right to buy) · traded 27 February 2020 · filed 14 April 2020
- gave away 24,000 shares of Provention Bio (a derivative holding)SEC Form 414 April 2020Employee Stock Option (right to buy) · traded 27 February 2020 · filed 14 April 2020
- exercised options over 32,246 shares of Provention BioSEC Form 414 April 2020Common Stock par value $0.0001 per share · traded 10 April 2020 · filed 14 April 2020
- was granted 24,000 shares of Provention Bio (a derivative holding)SEC Form 425 June 2019Option (right to buy) · traded 24 June 2019 · filed 25 June 2019
- ▼ sold on the open market 7,300 shares of Provention BioSEC Form 417 June 2019Common Stock · traded 17 June 2019 · filed 17 June 2019
- was granted 128,981 shares of Provention Bio (a derivative holding)SEC Form 428 March 2019Option (right to buy) · traded 27 March 2019 · filed 28 March 2019
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.